Regulatory Information
DKSH SINGAPORE PTE. LTD.
DKSH SINGAPORE PTE. LTD.
Therapeutic
Prescription Only
Formulation Information
CREAM
**Dosage and administration** Cutaneous use. Travocort should be applied twice daily to the diseased areas of skin. The treatment with Travocort must be terminated after regression of the inflammatory or eczematous skin condition, at the latest, however, after 2 weeks, and the therapy continued or followed up with a glucocorticoid-free anti-fungal preparation. This applies in particular for use in the inguinal and genital regions.
TOPICAL
Medical Information
**Indications** Initial or interim treatment of those superficial fungal infections of the skin which are accompanied by highly inflammatory or eczematous skin conditions, e.g. in the region of the hands, the interdigital spaces of the feet, and the inguinal and genital regions.
**Contraindications** Tuberculous or syphilitic processes in the area to be treated; virus diseases (e.g. varicella, herpes zoster), rosacea, perioral dermatitis and postvaccination skin reactions in the area to be treated.
D01AC20
imidazoles/triazoles in combination with corticosteroids
Manufacturer Information
DKSH SINGAPORE PTE. LTD.
LEO Pharma Manufacturing Italy S.r.I
Active Ingredients
Documents
Package Inserts
063581_3.pdf
Approved: September 27, 2019